## INTERNATIONAL SEARCH REPORT

-----ational Application No

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/66 A61K A61K31/505 A61K31/506 A61P35/00 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages 1-26 WO 99/02166 A (ANGIOGENE PHARM LTD ; DOUGHERTY GRAEME (GB)) 21 January 1999 (1999-01-21) cited in the application page 12, line 17 - page 13, line 7; example 1 1 - 26Y "CONTINUING THE FIGHT AGAINST BLEIBERG H: ADVANCED COLORECTAL CANCER: NEW AND FUTURE TREATMENT OPTIONS" ANTI-CANCER DRUGS, RAPID COMMUNICATIONS, OXFORD, GB, vol. 9, no. 1, January 1998 (1998-01), pages 18-28, XP000882025 ISSN: 0959-4973 page 19, column 1, lines 43-46 page 20, line 13 \_/---Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. \*O\* document referring to an oral disclosure, use, exhibition or document published prior to the international filing date but later than the priority date claimed \*&\* document member of the same patent family Date of malling of the international search report Date of the actual completion of the international search 26/11/2004 23 September 2004 Name and mailing address of the ISA Authorized officer Ruropean Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016 Allnutt, S

## INTERNATIONAL SEARCH REPORT

i tional Application No

		1-01/GB2004/002024	
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.	
A	WO 01/74368 A (ANGIOGENE PHARM LTD; DAVIS PETER DAVID (GB); DOUGHERTY GRAEME (US)) 11 October 2001 (2001-10-11) claim 1	1-26	
A	SIEMANN D W ET AL: "TARGETING TUMOR BLOOD VESSELS: AN ADJUVANT STRATEGY FOR RADIATION THERAPY" RADIOTHERAPY AND ONCOLOGY, AMSTERDAM, NL, vol. 57, no. 1, 1 October 2000 (2000-10-01), pages 5-12, XP001007731 page 7, column 1, line 8 page 9, column 1, lines 30-33	1-26	

nternational application No.
PCT/GB2004/002624

## INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This international Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: 18-26 because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 18-26 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest  The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No. . . T/GB2004/002624

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9902166	A	21-01-1999	AU	741213 B2	29-11-2001
	- •		AU	8231198 A	08-02-1999
			BR	9810681 A	15-08-2000
			CA	2292549 A1	21-01-1999
			CN	1262624 T	09-08-2000
			EΡ	10 <b>0</b> 1785 A1	24-05-2000
			wo	99O2166 A1	21-01-1999
			ĤŬ	00O2493 A2	28-08-2001
			ID	25483 A	05-10-2000
			ĴΡ	3455549 B2	14-10-2003
			JΡ	20015 <b>1</b> 5516 T	18-09-2001
			NO	20000077 A	07-01-2000
			NZ	501341 A	31-08-2001
			PL	337926 A1	11-09-2000
			SK	132000 A3	11-12-2000
			TR	99O3149 T2	21-09-2000
			US	6423753 B1	23-07-2002
WO 0174368	Α	11-10-2001	AU	4258101 A	15-10-2001
			AU	4258601 A	15-10-2001
			BR	01 <b>0</b> 9671 A	04-02-2003
			BR	01 <b>0</b> 9672 A	04-02-2003
			CA	24 <b>0</b> 2078 A1	11-10-2001
			CA	24 <b>0</b> 2539 A1	11-10-2001
			CN	1430515 T	16-07-2003
			CN	1422157 T	04-06-2003
			CZ	20023228 A3	15-01-2003
•			CZ	20023231 A3	15-01-2003
			EE	2002 <b>0</b> 0549 A	16-02-2004
			EE	2002 <b>0</b> 0565 A	15-06-2004
			EP	1272199 A1	08-01-2003
			EP	1272200 A1	08-01-2003
			MO	0174368 A1	11-10-2001
			MO	0174369 A1	11-10-2001
			HU	030 0290 A2	28-06-2003
			HU	030 0576 A2	28-07-2003
			JP	2003528920 T	30-09-2003
			JP	2003528921 T	30-09-2003
			NO	2002 4646 A	15-10-2002
			NO	2002 4683 A	15-10-2002
			PL	35 7282 A1	26-07-2004
			SK	1390 2002 A3	02-05-2003
			SK	1391 2002 A3	02-05-2003
			US	200305 5024 A1	20-03-2003
			US	2003166617 A1	04-09-2003
			ŽĀ	200207108 A	04-12-2003
			ZA	200207114 A	04-02-2004